Tamoxifen or Etoposide for recurring brain tumor after prior treatment
Part of Cancer clinical trials.
This trial tests whether tamoxifen works as well as etoposide in people whose glioblastoma has come back after standard chemotherapy and radiation with temozolomide. It aims to find a better medication option for controlling the tumor after the first return.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have glioblastoma (GBM) proven by tissue testing, and it has progressed after your first treatment with temozolomide plus radiation
- Your MRI shows at least one measurable tumor spot (about 10 mm or larger) that can be seen in scans taken at least 2 different slice levels
- You did not receive radiation within the last 3 months before the tumor was found to be progressing
- Your steroid medicine (like dexamethasone) dose is stable or going down, and you’re on the lowest dose needed to control swelling symptoms
- Your general fitness level is good enough (ECOG 0 to 2), and you’re between 18 and 65 years old
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
This trial tests two different combinations of chemotherapy drugs given directly into the artery that feeds the brain tumor. It is for people with glioblastoma (a type of brain tumor) that has continued to grow after standard treatment.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.